Augmedix (AUGX) Osake Kurssi
Augmedix Kurssi
Liikevaihto on kasvanut 33,5 % vuodessa viimeisten 4 vuoden aikana 44,86 M USD:een. Augmedixn nettomarginaali on nyt −42,7 %, noussut −158,5 %:sta muutama vuosi sitten. Analyytikoiden mediaanitavoitehinta on 2,98 USD, eli yli nykyhintaa 27,0 %. 10 analyytikosta 7 suosittaa ostoa — kokonaiskonsensus on Osta.
Augmedix osakekurssi
Augmedix liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Augmedix -osakkeesta
The business model of Augmedix Inc revolves around providing remote medical scribe services to healthcare providers. Augmedix utilizes wearable technology, such as smart glasses, to capture and transmit real-time patient data to professional medical scribes. These scribes then document and transcribe the patient-physician interaction, allowing doctors to focus on patient care. Augmedix's innovative approach enhances physician productivity, reduces administrative burden, and improves healthcare services. By harnessing technology to optimize documentation, Augmedix enables more efficient and accurate patient record-keeping, ultimately leading to improved patient outcomes and streamlined workflows for healthcare providers.
Augmedix Inc is primarily active in the healthcare industry.
The main competitors of Augmedix Inc in the market are companies like Doximity, Notable, PrognoCIS, and Suki.
Augmedix Inc is a leading healthcare technology company specialized in providing documentation solutions for doctors and physicians. Founded in 2012, Augmedix has revolutionized the healthcare industry by introducing a unique platform that enables healthcare professionals to focus more on patient care, rather than administrative tasks. Through their innovative technology, the company has successfully integrated artificial intelligence and virtual scribes to streamline the documentation process, improving efficiency and accuracy in medical records. Augmedix Inc has gained recognition for its transformative solutions, partnering with over 1,000 healthcare organizations worldwide. With its commitment to enhancing patient care, Augmedix continues to spearhead advancements in healthcare documentation services.
Augmedix Inc has achieved several significant milestones. Firstly, the company secured major funding rounds, raising a total of $90 million in investment. Secondly, Augmedix expanded its operations by partnering with leading healthcare providers and successfully implementing its virtual medical documentation platform. Thirdly, the company received recognition and awards, including being named one of the Most Innovative Companies in Healthcare by Fast Company. Additionally, Augmedix has witnessed substantial growth with its platform being used by healthcare professionals across numerous clinics and hospitals. These milestones highlight Augmedix Inc's success in revolutionizing the healthcare industry with its innovative technology and services.
Augmedix Inc is primarily present in the United States.
Augmedix Inc represents values of innovation, efficiency, and patient-centricity. As a leading provider of remote medical documentation services, Augmedix is committed to revolutionizing healthcare through the use of advanced technology. The company's corporate philosophy revolves around enhancing the healthcare experience for both patients and providers. Augmedix leverages its proprietary platform to streamline clinical workflows, allowing healthcare professionals to focus on delivering high-quality care. By embracing a patient-centric approach, the company aims to improve access to healthcare services, reduce administrative burdens, and ultimately enhance patient outcomes. Augmedix Inc's dedication to innovation and efficiency sets it apart in the rapidly evolving digital healthcare industry.
Analyytikot asettavat tällä hetkellä Augmedix-osakkeelle keskimääräisen tavoitehinnan 3,60 USD (mediaani: 2,98 USD), mikä merkitsee +53,0 % viimeisimpään hintaan verrattuna. Konsensus perustuu 10 analyytikkoarvioon.
10 analyytikkoa arvioi tällä hetkellä Augmedix-osaketta: 7 suosittaa ostoa, 3 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Augmedix-yhtiöltä 62,00 M USD liikevaihtoa ja −0,35 USD osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Augmedix-osake noteerataan hintaan 2,10 EUR (2,35 USD).
Augmedix-osake (AUGX) on listattuna 1 pörssissä, muun muassa: NASDAQ (AUGX).
Augmedix Inc is a leading company in the field of medical records and workflow improvement. The company's business model is based on the implementation of virtual reality (VR) and artificial intelligence (AI) for the automatic creation of medical documentation. Augmedix specializes in efficiently serving doctor's offices, hospitals, and insurance companies. Augmedix's main product is an intuitive application that allows doctors to treat their patients more efficiently and quickly by reviewing medical records and providing diagnoses and treatments. The use of VR technology allows medical professionals to access relevant information while interacting with patients. Augmedix's AI saves doctors time and increases efficiency by automatically performing necessary steps while doctors focus on treating patients. The company also offers additional services and support to facilitate the integration of their technology into existing practice and workflow. By improving the efficiency and accuracy of medical documentation, Augmedix helps doctors increase productivity and optimize patient care. Additionally, Augmedix's technology saves time and costs for practice management, improving the operation of doctor's offices and hospitals. Augmedix also provides specialized training to educate medical professionals in VR technology and AI. The company has partnerships with major healthcare organizations such as Sutter Health and Dignity Health to implement the technology and enhance patient care. Augmedix's business model is based on a subscription model, where customers pay for access to the technology and related services. The average price for a monthly subscription is around $2,500 per doctor. The company is able to achieve high margins due to the high value of its services, the high quality of its technology, and the high demand for automation of medical records. Augmedix Inc is also expanding internationally and has already offered services in Canada, the UK, and Australia. The company has a strategic partnership with Google to further improve and expand its technology. It has also become a central element in the telehealth market, which has gained importance during the COVID-19 pandemic. In summary, Augmedix Inc's business model specializes in improving workflows in healthcare and automating medical records. Augmedix's technology is based on VR and AI to help doctors and medical professionals perform their work more efficiently and accurately. The company offers a variety of services and training to integrate its technology into existing practice and workflow. Augmedix's subscription model allows the company to achieve high margins and competitive advantages in a rapidly growing market.
odotettu liikevaihto Augmedix on 62,00 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Augmedix on −17,30 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Augmedix:n hinta-voitto-suhde (P/E) on tällä hetkellä −6,66. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Augmedix-osakkeen arvostusta.
Augmedix:n hinta-myynti-suhde (P/S) on tällä hetkellä 1,86. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Augmedix-osakkeen arvostuskennuslukuna.
Augmedix:n Eulpool-laatuscore on 3/10.
Augmedix:n ISIN on US05105P1075. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Augmedix:n ticker on AUGX. Tämä pörssinoteeraus käytetään Augmedix-osakkeiden kauppaan pörssissä.
Augmedix osake
Augmedix vertaisryhmä
Augmedix Ticker
Augmedix FIGI
Kaikki tunnusluvut ja syvällinen analyysi Augmedix:sta
Meidän osakeanalyysimme Augmedix-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Augmedix:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: